Skip to content

Media

Highlights of Aztiq's investments. Aztiq is an investment company focused on working with purpose-driven pharmaceutical and biotechnology companies that are dedicated to improving the lives of people all over the world.

News

All companies

All categories

July 3, 2023Company newsLotus

Aztiq and Innobic Announce Pricing of Secondary Sale of Lotus Common Stock by AEMH

Read more

June 5, 2023Company newsLotus

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

Read more

April 12, 2023Investment newsAlvotech

Mitsui Acquires Convertible Bonds Issued by Alvotech and Forges Strategic Healthcare Collaboration Agreement with Aztiq

Read more

February 10, 2023Company newsLotus

Lotus Reported Unaudited January Revenues of NT$2,007 Million, a 112% YoY Growth

Read more

February 9, 2023Company newsAlvotech

EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Read more

January 25, 2023Company newsAlvotech

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Read more

January 23, 2023Company newsAlvotech

Alvotech Completes $137 Million Private Share Placement

Read more

January 20, 2023Company newsAdalvo

Adalvo extends its strategic collaboration with Bioventure, the subsidiary of Healthcare Division of Yas Holding, within the MENA region

Read more

January 16, 2023Company newsLotus

Lotus Obtains Tentative Approval for Nintedanib ANDA from the US FDA

Read more

January 13, 2023Company newsAlvotech

Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

Read more

January 12, 2023Company newsAdalvo

Adalvo and STADA extend their strategic partnership

Read more

January 11, 2023Company newsAlvotech

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Read more

January 10, 2023Company newsLotus

Lotus Ends 2022 on a Strong Note, with Full Year Revenue up 15.7% over Last Year

Read more

January 10, 2023Company newsAdalvo

Zentiva extends its collaboration with Adalvo and strengthens its offering in Respiratory, CNS and Dermatology

Read more

Two Alvotech staff members

January 6, 2023Company newsAlvotech

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Read more

January 5, 2023Company newsLotus

Lotus Obtained Another Exclusive Right of Cancer Injectable Drug Across Asia

Read more

December 28, 2022Company newsAdalvo

Adalvo and Frontier Biopharma/Zdravlje Sign Licensing & Supply Agreement for Central & Eastern Europe

Read more

December 22, 2022Company newsAlvotech

Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®

Read more

December 16, 2022Company newsAlvotech

Alvotech Completes $70 Million Private Placement

Read more

December 13, 2022Company newsLotus

Lotus acquires Alimta® (Pemetrexed) in Taiwan from Lilly

Read more

December 9, 2022Company newsLotus

Lotus Monthly sales report for November 2022

Read more

December 8, 2022Company newsAlvotech

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

Read more

December 7, 2022Company newsAlvotech

Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

Read more

Merki Adalvo

December 6, 2022Company newsAdalvo

Adalvo signs licensing deal with MS Pharma for Solifenacin + Tamsulosin

Read more

Róbert Wessman Aztiq Founder and Chairman

December 2, 2022Company newsAlvotech

Alvotech Announces Changes to its Leadership Team

Read more

Róbert Wessman Aztiq Founder and Chairman

December 1, 2022Company newsAlvotech

Alvotech Announces Changes to its Leadership Team

Read more

November 26, 2022Company newsAdalvo

Adalvo and Aristo Pharma sign licensing & supply agreement to commercialise a basket of products

Read more

November 16, 2022Company newsAlvotech

Alvotech secures financing facilities of approximately $136 Million

Read more

November 15, 2022Company newsAlvotech

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

Read more

November 10, 2022Company newsLotus

Lotus reports its best quarter ever with the biggest launch in its history

Read more

October 19, 2022Company newsAlvotech

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

Read more

October 17, 2022Company newsAlvotech

Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

Read more

October 12, 2022Company newsAlvotech

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Read more

Marki Adalvo

September 29, 2022Company newsAdalvo

Adalvo and Actor Pharmaceuticals Sign Exclusive Licensing Agreement to Commercialise a Basket of Products in the Australian Market

Read more

September 5, 2022Company newsLotus

Lotus Launches Lenalidomide Capsules, Generic Version of Revlimid®, in the US

Read more

September 2, 2022Company newsAlvotech

Alvotech Reports First Half 2022 Financial Results

Read more

August 29, 2022Company newsAlvotech

Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data

Read more

August 26, 2022Company newsAdalvo

Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets

Read more

August 25, 2022Company newsAlvotech

Alvotech Initiates Confirmatory Patient Study for AVT03

Read more

Visual element, triangle on a dark blue background

August 25, 2022Company newsLotus

Lotus Receives Tentative Approval for Midostaurin ANDA from the US FDA

Read more

August 23, 2022Company newsAdalvo

Adalvo advances in the pain domain, offering an extensive portfolio of pain management medication

Read more

August 16, 2022Company newsLotus

Lotus and Fuji Pharma submitted 1st co-developed high value generic product in Japan

Read more

August 12, 2022Company newsAlvotech

Alvotech prepares listing on Nasdaq main market in Iceland

Read more

August 9, 2022Company newsAdalvo

Adalvo Announces successful DCP closure for Fulvestrant pre-filled injection

Read more

August 8, 2022Company newsLotus

Lotus monthly sales report for July 2022

Read more

August 2, 2022Company newsAdalvo

Adalvo acquires its first branded product, Onsolis®

Read more

July 20, 2022Company newsAlvotech

Alvotech initiates a pharmacokinetic study for AVT03

Read more

Merki Adalvo

July 15, 2022Company newsAdalvo

Adalvo announces DCP approval for Dimethyl Fumarate 120mg, 240mg hard capsules

Read more

July 14, 2022Company newsAlvotech

Alvotech expands its Board of Directors

Read more

July 11, 2022Company newsLotus

Lotus announced that its consolidated sales for June 2022 was NT$1,040,734 thousand

Read more

Share